Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

Key facts

Sponsor

Elizabeth Austen Lawson

Principal Investigator

Elizabeth A Lawson, MD, MMSc

Massachusetts General Hospital

Intervention

Intranasal Oxytocin (IN-OXT)(drug)

Enrollment

40 enrolled

Eligibility

18 years · All sexes

Timeline

2025 – 2026

Study locations (1)

• Massachusetts General Hospital, Neuroendocrine Unit, Boston, Massachusetts, United States

Collaborators

Tonix Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Arginine vasopressin deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07361263
  Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency
  University Hospital, Basel, Switzerland
• RECRUITINGPHASE2NCT06808516
  Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls
  University Hospital, Basel, Switzerland
• RECRUITINGPHASE2NCT06676774
  Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls
  University Hospital, Basel, Switzerland
• RECRUITINGNANCT06789705
  Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls
  University Hospital, Basel, Switzerland
• RECRUITINGEARLY PHASE1NCT06460948
  Identifying Oxytocin Deficiency in Adults With Pituitary Disease
  Elizabeth Austen Lawson
• RECRUITINGNCT06422975
  Registry of Patients in Shock Treated With Vasopressin
  Hospital Universitario 12 de Octubre

See all trials for Arginine vasopressin deficiency →